{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.000","upperLimit":"109.100","value":"88.10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"Overall Survival was defined as the time from the start of study treatment to the death due to any cause. For participants who were still alive at the time of the data cutoff, survival data were censored at the latest available date the participant was known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Lenalidomide 25 mg administered orally once daily (QD) until progressive disease or unacceptable toxicity","id":"OG000","title":"Lenalidomide"}],"paramType":"MEDIAN","populationDescription":"The EE population consisted of all participants who met basic protocol requirements (all eligibility criteria) and were evaluated after receiving at least one dose of lenalidomide.","reportingStatus":"POSTED","timeFrame":"From Day 1 of study treatment to disease progression or death; up to final data cut-off date of 19 May 2017; maximum surivival time was 197.9 weeks","title":"Kaplan-Meier Estimate for Overall Survival","type":"SECONDARY","unitOfMeasure":"weeks"}